BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Anergis 

Biopôle III
Route de la Corniche 9B
  Epalinges  CH-1066  Switzerland
Phone: 41-21-651-92-20 Fax: 41-21-651-92-21


SEARCH JOBS




Industry
Biotechnology






 Company News
Anergis Granted U.S. Patent For Ragweed Allergy Vaccine AllerR 12/19/2014 10:41:18 AM
Anergis Starts Phase II Dose Ranging Trial With Birch Pollen Allergy Vaccine AllerT 12/11/2014 6:40:00 AM
Anergis Reports Positive Long-Term Clinical Efficacy Of Lead Compound AllerT 9/16/2014 11:33:21 AM
Anergis Appoints Dr. Vanya Beltrami As Director Product Development 6/3/2014 10:05:05 AM
Anergis To Present New COP Allergy Vaccine Data At European Academy of Allergology and Clinical Immunology Conference 2014 In Copenhagen 5/27/2014 1:34:43 PM
Anergis Completes Enrolment In The Long-Term Efficacy Trial Of Lead Compound AllerT 4/23/2014 11:26:33 AM
Phase 2b Results Of Anergis' Lead Compound Allert To Be Presented At 2014 American Academy of Dermatology Annual Meeting In San Diego 2/27/2014 8:14:27 AM
Anergis Closes Financing Round Totaling CHF 8 Million 2/5/2014 6:04:14 AM
Anergis Obtains Core Technology Patent In Japan 1/14/2014 9:43:42 AM
Immunology Data Further Underline the Positive Outcome of a Phase IIb Trial of Anergis' Birch Pollen Allergy Vaccine AllerT 10/21/2013 8:48:47 AM
12